source
- Biogen’s early Phase 2 data supports tau-targeting Alzheimer’s approachBiogen has released early Phase 2 results for its experimental Alzheimer’s therapy diranersen, indicating that reducing tau protein levels may lead to cognitive benefits. The findings add to a lon…
- J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotechThe in vivo CAR-T space is getting more competitive as one of the biggest cell therapy players expands its role. Johnson & Johnson is paying $785 million upfront to work with Flagship Pioneering's…Endpoints · 1h ago↗ source